Video

Dr. Stephens on Pivotal Data From ELEVATE-RR Trial in Previously Treated CLL

Deborah M. Stephens, DO, discusses the phase 3 ELEVATE-RR trial comparing the safety and efficacy of acalabrutinib with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Video Player is loading.
Current Time 0:00
Duration 0:56
Loaded: 0%
Stream Type LIVE
Remaining Time 0:56
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Deborah M. Stephens, DO, director of the CLL and Lymphoma Program, Huntsman Cancer Institute, discusses the phase 3 ELEVATE-RR trial (NCT02477696) comparing the safety and efficacy of acalabrutinib (Calquence) with ibrutinib (Imbruvica) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). 

Results from the study showed no difference in efficacy between the 2 agents with regard to progression-free survival, according to Stephens. However, acalabrutinib showed a more favorable toxicity profile compared with ibrutinib in these patients, Stephens adds.

Acalabrutinib is a feasible option for this population, and its favorable toxicity profile may result in increased utilization of the agent, Stephens concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data